Sangamo Therapeutics, Inc. (SGMO) Just Recorded A Sigfniciant Increase

December 7, 2017 - By Kurt Siggers

Investors sentiment increased to 1.59 in 2017 Q2. Its up 0.79, from 0.8 in 2017Q1. It is positive, as 13 investors sold Sangamo Therapeutics, Inc. shares while 31 reduced holdings. 33 funds opened positions while 37 raised stakes. 50.83 million shares or 24.82% more from 40.72 million shares in 2017Q1 were reported.
Marshall Wace Llp, a United Kingdom-based fund reported 56,314 shares. Susquehanna Llp holds 0% or 203,734 shares in its portfolio. Tudor Inv Corporation Et Al has 26,507 shares for 0.01% of their portfolio. State Of Wisconsin Invest Board invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Metropolitan Life Insur holds 0% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 48,332 shares. Trexquant L P owns 82,478 shares. Bourgeon Mgmt Limited Liability Corporation invested in 0.06% or 11,500 shares. Tocqueville Asset Limited Partnership owns 355,015 shares. Sg Americas Secs Ltd Company stated it has 70,909 shares or 0.01% of all its holdings. California Public Employees Retirement Systems has invested 0% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Alliancebernstein Ltd Partnership owns 90,241 shares. 34,008 are owned by Barclays Pcl. Nelson Roberts Limited Liability Company holds 0.01% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 3,000 shares. Moreover, Eam Ltd has 0.16% invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Geode Mngmt Limited Liability holds 0% or 727,615 shares in its portfolio.

The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is a huge mover today! The stock increased 5.20% or $0.85 during the last trading session, reaching $17.2. About 1.37 million shares traded. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has risen 29.78% since December 7, 2016 and is uptrending. It has outperformed by 13.08% the S&P500.
The move comes after 8 months positive chart setup for the $1.45B company. It was reported on Dec, 7 by Barchart.com. We have $18.06 PT which if reached, will make NASDAQ:SGMO worth $72.70M more.

Analysts await Sangamo Therapeutics, Inc. (NASDAQ:SGMO) to report earnings on February, 27. They expect $-0.23 EPS, down 64.29 % or $0.09 from last year’s $-0.14 per share. After $-0.15 actual EPS reported by Sangamo Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 53.33 % negative EPS growth.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Ratings Coverage

Among 10 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 6 have Buy rating, 1 Sell and 3 Hold. Therefore 60% are positive. Sangamo Biosciences had 21 analyst reports since August 8, 2015 according to SRatingsIntel. The firm has “Neutral” rating by PiperJaffray given on Wednesday, October 19. The company was maintained on Saturday, August 8 by JP Morgan. The firm has “Hold” rating given on Monday, August 14 by Wedbush. As per Friday, September 4, the company rating was maintained by Cowen & Co. The rating was maintained by Wedbush with “Hold” on Wednesday, November 15. The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) earned “Buy” rating by Wedbush on Wednesday, September 2. The rating was initiated by Wells Fargo with “Outperform” on Friday, December 4. Piper Jaffray maintained it with “Hold” rating and $800 target in Thursday, August 10 report. The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has “Neutral” rating given on Thursday, August 4 by Janney Capital. The firm has “Buy” rating given on Thursday, September 3 by JP Morgan.

More notable recent Sangamo Therapeutics, Inc. (NASDAQ:SGMO) news were published by: Seekingalpha.com which released: “Sangamo’s Powerful Pipeline Drives Significant Upside” on November 17, 2017, also Nasdaq.com with their article: “Commit To Buy Sangamo Therapeutics At $8, Earn 21.9% Using Options” published on November 08, 2017, Nasdaq.com published: “Sangamo Therapeutics (SGMO) in Focus: Stock Moves 13.6% Higher” on November 16, 2017. More interesting news about Sangamo Therapeutics, Inc. (NASDAQ:SGMO) were released by: Seekingalpha.com and their article: “Sangamo Therapeutics: Engineering Genomic Solutions For Rare Diseases” published on December 07, 2017 as well as Fool.com‘s news article titled: “Here’s Why Sangamo Therapeutics Rose as Much as 14.9% Thursday” with publication date: November 30, 2017.

Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company has market cap of $1.45 billion. The companyÂ’s proprietary zinc finger DNA-binding protein technology enables specific genome editing and gene regulation. It currently has negative earnings. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.